Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9MW0813
- Development stage
- Approved
- Lead developer
- Mabwell
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
9MW0813 is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein developed as an intravitreal injection for the treatment of diabetic macular edema (DME). It acts as a vascular endothelial growth factor (VEGF) inhibitor by binding VEGF and preventing its interaction with receptors, thereby reducing abnormal blood vessel growth and leakage in the retina. The drug is being developed by Mabwell (Shanghai) Bioscience and is currently in Phase III clinical trials comparing its efficacy and safety to aflibercept (EYLEA®), a standard treatment for DME. The primary administration route is intravitreal injection. It has not yet received regulatory approval.
- Brand names
- AfqlirEnzeevu
- Other names
- aflibercept biosimilar
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on 9MW0813.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9MW0813.